Status:
COMPLETED
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Collaborating Sponsors:
Gesellschaft für Therapieforschung mbH
Conditions:
Relapsing-Remitting Multiple Sclerosis
Eligibility:
All Genders
Brief Summary
This was an observational, single arm, multicentric study conducted for the adjustment of treatment strategy and its monitoring using high-frequency and high-dosage administration of interferon-beta (...
Detailed Description
Treatment of MS, which progresses to attacks or episodes, with interferon-beta has established itself as therapy of the first choice. On the basis of different studies, the hypothesis was substantiate...
Eligibility Criteria
Inclusion
- Subjects with clinically ensured diagnosis of a MS and history of attacks or episodes
- Subjects who were on one of the permitted basis therapies at least since 6 months
- Subjects with existing systemic concurrent diseases (e.g.diabetes, heart, liver, kidney diseases) should be monitored very carefully.
Exclusion
- Subjects with secondary progressive course of the MS without attacks or episodes, pregnant or nursing subjects as well as subjects with history of contraindications
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
231 Patients enrolled
Trial Details
Trial ID
NCT01142453
Start Date
May 1 2005
End Date
June 1 2008
Last Update
July 14 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.